Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | F11 | P03951 | 2/20 | 0.51 |
| ▸ | F7 | P08709 | 2/20 | 0.51 |
| ▸ | CDK4 | P11802 | 6/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.46 |
| ▸ | CCND1 | P24385 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CCND3 | P30281 | 6/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973109 | 0.81 | F10 (0.52) | F9F10F11F7CDK4 | |
| SCHEMBL7975272 | 0.80 | ITK (0.63) | F9F10F11F7CDK4 | |
| SCHEMBL7975946 | 0.79 | KDM4E (0.68) | F9F10F11F7CDK4 | |
| SCHEMBL10139790 | 0.78 | F9 (0.56) | F9F10F11F7ITK | |
| SCHEMBL10139794 | 0.78 | F9 (0.56) | F9F10F11F7ITK | |
| SCHEMBL10172578 | 0.78 | F9 (0.56) | F9F10F11F7CDK4 | |
| SCHEMBL7982406 | 0.78 | KDM4E (0.50) | F9F10F11F7CDK4 | |
| SCHEMBL7973887 | 0.76 | F10 (0.70) | F9F10F11F7KDM4E | |
| SCHEMBL10139800 | 0.76 | CHEK1 (0.56) | F9F10F11F7KDM4E | |
| SCHEMBL7976096 | 0.75 | CHEK2 (0.54) | F9F10F11F7CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-B1 | Heterocyclic compounds as factor IXA inhibitors. | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | F9 1/4885F10 11/4885F11 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.